Business Context and Reporting Period
Company: Cardiff Oncology, Inc. (CRDF)
Filing Type: Form 8-K (Current Report)
Date of Report: September 14, 2026
Context: The Company entered into a Confidential Settlement Agreement and Release with Nerviano Medical Sciences, S.r.l. ("Nerviano") to resolve pending litigation regarding inventorship of certain patents and performance under a 2017 License Agreement for the molecule onvansertib.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The settlement involved no monetary payment between the parties. However, the accompanying Amendment to the License Agreement introduces future financial obligations and potential inflows:
- License Fees: An additional license fee payable by Cardiff to Nerviano on annual net sales of products practicing valid claims of a Company patent, replacing the prior royalty structure.
- Milestone Payments: Development milestones and potential performance-related payments tied to Cardiff's upcoming Phase 3 program.
- Assignment Proceeds: Revised provisions requiring Cardiff to pay Nerviano a percentage of transaction proceeds if rights are assigned (e.g., via merger or change of control) before Phase III data readout.
- Post-Termination Royalties: Revised tiers payable by Nerviano to Cardiff depending on the development stage or regulatory approval achieved at the time of termination.
Material Changes Versus Prior Period
The primary material change is the resolution of the litigation (Case No. 3:26-cv-03131-RBM-JLB) and the amendment of the 2017 License Agreement. Key changes include:
- Exclusivity: Implementation of an updated framework preventing Nerviano from clinically developing or commercializing competing products or onvansertib during the royalty term.
- Governance: Nerviano has been granted a board observer seat and a seat on Cardiff's Scientific Advisory Board, along with enhanced Joint Development Committee provisions.
- Termination Rights: Termination-for-cause provisions now require a judicial or arbitral determination of material breach before the agreement can be terminated.
Guidance, Outlook, and Risks
Outlook: The settlement clears the path for Cardiff's upcoming Phase 3 program for onvansertib without the distraction of ongoing litigation. The amended agreement aligns the commercial interests of both parties through revised royalty and milestone structures.
Risks and Contingencies:
- Financial Obligations: Future cash outflows are contingent on sales performance, Phase 3 milestones, and potential change-of-control transactions.
- Operational Control: Nerviano's new board observer and advisory roles may influence strategic decisions regarding onvansertib development.
- Legal Finality: The Amendment becomes fully operative only upon the dismissal of the litigation with prejudice.
Investor Verification Checklist
- Verify the specific percentage of transaction proceeds owed to Nerviano in the event of a change of control prior to Phase III readout.
- Review the detailed schedule of development milestones and performance-related payments for the Phase 3 program.
- Confirm the exact terms of the "additional license fee" on annual net sales replacing the previous royalty rate.
- Assess the impact of Nerviano's board observer seat on future corporate governance and strategic direction.
- Examine the full text of the Amendment (Exhibit 10.1) for redacted portions that may contain critical financial thresholds.